視神経障害管理の世界市場レポート 2025年

視神経障害管理市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.0％で48億5,000万米ドルに成長します。予測期間の成長は、アメーバ感染症に罹患する人の増加、高齢者人口の増加、視神経炎の有病率の上昇、緑内障の発生率の上昇、視神経炎症例の全体的な増加に起因しています。主な動向としては、医療技術の進歩、個別化医療や遠隔医療の台頭、診断技術の技術的向上、新興市場におけるヘルスケアインフラの拡大、神経保護療法への注目の高まりなどが挙げられます。

眼疾患の有病率の増加は、今後数年間の視神経障害管理市場の成長を牽引すると予想されます。眼疾患には、目の構造や機能に影響を及ぼし、視力障害や関連症状を引き起こすあらゆる疾患が含まれます。このような症状の増加は、人口の高齢化、長時間のスクリーン露出、不健康なライフスタイルの選択、糖尿病などの基礎的な健康問題などの要因に影響されています。視神経障害管理は、視神経のさらなる損傷を防ぎ、視力を維持することで、眼疾患の影響を軽減する上で重要な役割を果たしています。例えば、2025年2月、英国の政府機関である保健社会福祉省は、英国では約200万人がある程度の視力喪失を抱えながら生活していると報告し、2030年までに270万人に増加するとの予測を示しました。その結果、眼疾患の有病率の増加が視神経障害管理市場の拡大に拍車をかけています。

視神経障害管理市場の主要企業は、競争優位性を獲得するため、モノクローナル抗体治療などの革新的治療に注力しています。モノクローナル抗体は、ウイルスや細菌などの有害な病原体と闘う免疫系の能力を模倣するように設計された、研究室で設計されたタンパク質です。例えば、2023年3月、アイルランドに本社を置くホライゾン・セラピューティクス社は、同社の医薬品であるアップリズナ（イネビリズマブ）のMRI所見に関する新たな分析を発表しました。この研究により、アップリズナは視神経脊髄炎スペクトラム障害（NMOSD）患者の無症候性視神経病変の形成を抑制することが明らかになりました。この結果は、Horizon社が視神経脊髄炎スペクトラム障害、痛風、甲状腺眼症などの希少疾患に対する先進的な治療法の開発に取り組んでいることを示すものです。アップリズナは、有害なB細胞を標的として排除するモノクローナル抗体で、炎症を抑え、中枢神経系と視神経のさらなる損傷を予防し、最終的に再発を予防して視力を維持するよう設計されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界視神経障害管理PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の視神経障害管理市場：成長率分析
• 世界の視神経障害管理市場の実績：規模と成長, 2019-2024
• 世界の視神経障害管理市場の予測：規模と成長, 2024-2029, 2034F
• 世界視神経障害管理総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の視神経障害管理市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• 手術
• その他の治療の種類
• 世界の視神経障害管理市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像検査
• 血液検査
• その他の診断
• 世界の視神経障害管理市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• その他のエンドユーザー
• 世界の視神経障害管理市場、医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 神経保護剤
• 抗酸化物質
• 免疫抑制剤
• プロスタグランジン類似体
• 世界の視神経障害管理市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 視神経減圧手術
• 視神経移植
• 網膜インプラント手術
• 世界の視神経障害管理市場、その他の治療タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低視力補助具
• 幹細胞療法
• 遺伝子治療

第7章 地域別・国別分析

• 世界の視神経障害管理市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の視神経障害管理市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 視神経障害管理市場：競合情勢
• 視神経障害管理市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Merck KGaA
• Teva Pharmaceuticals
• Otsuka Pharmaceutical Co. Ltd.
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Alexion Pharmaceuticals Inc.
• Horizon Therapeutics plc
• Santen Pharmaceutical Co. Ltd.
• Mallinckrodt Pharmaceuticals
• Aerie Pharmaceuticals
• Neurophth Therapeutics
• AdvaCare

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 視神経障害管理市場2029：新たな機会を提供する国
• 視神経障害管理市場2029：新たな機会を提供するセグメント
• 視神経障害管理市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Optic neuropathy management involves the diagnosis, treatment, and monitoring of optic nerve damage through medications, lifestyle modifications, surgical interventions, and vision rehabilitation to prevent further deterioration and improve visual function.

The primary treatment types for optic neuropathy management include medications, surgery, and other therapeutic approaches. Medications are used to treat, manage, or prevent diseases by altering bodily functions, such as reducing inflammation or protecting nerve function. Diagnosis typically involves imaging tests, blood tests, and other diagnostic procedures. Treatment is provided across various healthcare settings, including hospitals, specialty clinics, ambulatory surgical centers, and other medical facilities.

The optic neuropathy management market research report is one of a series of new reports from The Business Research Company that provides optic neuropathy management market statistics, including the optic neuropathy management industry global market size, regional shares, competitors with the optic neuropathy management market share, detailed optic neuropathy management market segments, market trends, and opportunities, and any further data you may need to thrive in the optic neuropathy management industry. This optic neuropathy management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The optic neuropathy management market size has grown strongly in recent years. It will grow from $3.62 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to the rising prevalence of optic neuropathy, an increasing number of eye injuries, greater investment in eye care services, growing demand for specialized eye care, and the rising incidence of diabetes and other chronic diseases.

The optic neuropathy management market size is expected to see strong growth in the next few years. It will grow to $4.85 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to the increasing number of individuals affected by amebic infections, a growing geriatric population, a rising prevalence of optic neuritis, a higher incidence of glaucoma, and an overall increase in optic neuritis cases. Key trends include advancements in medical technology, the rise of personalized medicine and telemedicine, technological improvements in diagnostic techniques, the expansion of healthcare infrastructure in emerging markets, and a growing focus on neuroprotective therapies.

The increasing prevalence of eye diseases is expected to drive the growth of the optic neuropathy management market in the coming years. Eye disease encompasses any condition that affects the structure or function of the eyes, leading to vision impairment or related symptoms. The rising occurrence of these conditions is influenced by factors such as aging populations, prolonged screen exposure, unhealthy lifestyle choices, and underlying health issues such as diabetes. Optic neuropathy management plays a crucial role in reducing the impact of eye diseases by preventing further optic nerve damage and preserving vision. For instance, in February 2025, the Department of Health and Social Care, a UK-based government department, reported that approximately 2 million people in the UK were living with some degree of sight loss, with projections indicating an increase to 2.7 million by 2030. As a result, the growing prevalence of eye disease is fueling the expansion of the optic neuropathy management market.

Leading companies in the optic neuropathy management market are focusing on innovative therapies, such as monoclonal antibody treatments, to gain a competitive edge. Monoclonal antibodies are lab-engineered proteins designed to mimic the immune system's ability to fight harmful pathogens such as viruses and bacteria. For example, in March 2023, Horizon Therapeutics, an Ireland-based company, presented a new analysis of MRI findings for its drug, UPLIZNA (inebilizumab). The study revealed that UPLIZNA reduces the formation of asymptomatic optic nerve lesions in patients with neuromyelitis optica spectrum disorder (NMOSD). This underscores Horizon's dedication to developing advanced treatments for rare conditions such as NMOSD, gout, and thyroid eye disease. UPLIZNA is a monoclonal antibody designed to target and eliminate harmful B cells, reducing inflammation and preventing further damage to the central nervous system and optic nerves, ultimately helping to prevent relapses and preserve vision.

In January 2024, Naya Biosciences, a US-based life sciences company, acquired Florida Biotechnologies for $20 million. This acquisition includes a gene therapy program aimed at treating Leber's hereditary optic neuropathy (LHON), a rare genetic disorder that leads to vision loss. Florida Biotechnologies is a US-based gene therapy company specializing in treatments for mitochondrial diseases, including LHON.

Major players in the optic neuropathy management market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc, Santen Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals, Aerie Pharmaceuticals, Neurophth Therapeutics, and AdvaCare.

North America was the largest region in the optic neuropathy management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in optic neuropathy management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the optic neuropathy management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The optic neuropathy management market consists of revenues earned by entities by providing services such as anti-inflammatory treatments, metabolic and nutritional support, and gene and stem cell therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The optic neuropathy management market includes sales of neuroprotective therapies, advanced imaging solutions, and AI-driven diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Optic Neuropathy Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on optic neuropathy management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for optic neuropathy management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The optic neuropathy management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medications; Surgery; Other Treatment Types
• 2) By Diagnosis: Imaging Tests; Blood Tests; Other Diagnosis
• 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Medications: Corticosteroids; Neuroprotective Agents; Antioxidants; Immunosuppressants; Prostaglandin Analogs
• 2) By Surgery: Optic Nerve Decompression Surgery; Optic Nerve Transplantation; Retinal Implant Surgery
• 3) By Other Treatment Types: Low Vision Aids; Stem Cell Therapy; Gene Therapy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Optic Neuropathy Management Market Characteristics

3. Optic Neuropathy Management Market Trends And Strategies

4. Optic Neuropathy Management Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Optic Neuropathy Management Growth Analysis And Strategic Analysis Framework

• 5.1. Global Optic Neuropathy Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Optic Neuropathy Management Market Growth Rate Analysis
• 5.4. Global Optic Neuropathy Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Optic Neuropathy Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Optic Neuropathy Management Total Addressable Market (TAM)

6. Optic Neuropathy Management Market Segmentation

• 6.1. Global Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Surgery
• Other Treatment Types
• 6.2. Global Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Tests
• Blood Tests
• Other Diagnosis
• 6.3. Global Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End-Users
• 6.4. Global Optic Neuropathy Management Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Neuroprotective Agents
• Antioxidants
• Immunosuppressants
• Prostaglandin Analogs
• 6.5. Global Optic Neuropathy Management Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Optic Nerve Decompression Surgery
• Optic Nerve Transplantation
• Retinal Implant Surgery
• 6.6. Global Optic Neuropathy Management Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low Vision Aids
• Stem Cell Therapy
• Gene Therapy

7. Optic Neuropathy Management Market Regional And Country Analysis

• 7.1. Global Optic Neuropathy Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Optic Neuropathy Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Optic Neuropathy Management Market

• 8.1. Asia-Pacific Optic Neuropathy Management Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Optic Neuropathy Management Market

• 9.1. China Optic Neuropathy Management Market Overview
• 9.2. China Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Optic Neuropathy Management Market

• 10.1. India Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Optic Neuropathy Management Market

• 11.1. Japan Optic Neuropathy Management Market Overview
• 11.2. Japan Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Optic Neuropathy Management Market

• 12.1. Australia Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Optic Neuropathy Management Market

• 13.1. Indonesia Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Optic Neuropathy Management Market

• 14.1. South Korea Optic Neuropathy Management Market Overview
• 14.2. South Korea Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Optic Neuropathy Management Market

• 15.1. Western Europe Optic Neuropathy Management Market Overview
• 15.2. Western Europe Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Optic Neuropathy Management Market

• 16.1. UK Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Optic Neuropathy Management Market

• 17.1. Germany Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Optic Neuropathy Management Market

• 18.1. France Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Optic Neuropathy Management Market

• 19.1. Italy Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Optic Neuropathy Management Market

• 20.1. Spain Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Optic Neuropathy Management Market

• 21.1. Eastern Europe Optic Neuropathy Management Market Overview
• 21.2. Eastern Europe Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Optic Neuropathy Management Market

• 22.1. Russia Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Optic Neuropathy Management Market

• 23.1. North America Optic Neuropathy Management Market Overview
• 23.2. North America Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Optic Neuropathy Management Market

• 24.1. USA Optic Neuropathy Management Market Overview
• 24.2. USA Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Optic Neuropathy Management Market

• 25.1. Canada Optic Neuropathy Management Market Overview
• 25.2. Canada Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Optic Neuropathy Management Market

• 26.1. South America Optic Neuropathy Management Market Overview
• 26.2. South America Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Optic Neuropathy Management Market

• 27.1. Brazil Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Optic Neuropathy Management Market

• 28.1. Middle East Optic Neuropathy Management Market Overview
• 28.2. Middle East Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Optic Neuropathy Management Market

• 29.1. Africa Optic Neuropathy Management Market Overview
• 29.2. Africa Optic Neuropathy Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Optic Neuropathy Management Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Optic Neuropathy Management Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Optic Neuropathy Management Market Competitive Landscape And Company Profiles

• 30.1. Optic Neuropathy Management Market Competitive Landscape
• 30.2. Optic Neuropathy Management Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Optic Neuropathy Management Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Merck KGaA
• 31.5. Teva Pharmaceuticals
• 31.6. Otsuka Pharmaceutical Co. Ltd.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Bausch Health Companies Inc.
• 31.9. Alexion Pharmaceuticals Inc.
• 31.10. Horizon Therapeutics plc
• 31.11. Santen Pharmaceutical Co. Ltd.
• 31.12. Mallinckrodt Pharmaceuticals
• 31.13. Aerie Pharmaceuticals
• 31.14. Neurophth Therapeutics
• 31.15. AdvaCare

32. Global Optic Neuropathy Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Optic Neuropathy Management Market

34. Recent Developments In The Optic Neuropathy Management Market

35. Optic Neuropathy Management Market High Potential Countries, Segments and Strategies

• 35.1 Optic Neuropathy Management Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Optic Neuropathy Management Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Optic Neuropathy Management Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer